Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to daraxonrasib, the company’s RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC in patients with KRAS G12 mutations. The Breakthrough Therapy Designation is based on data from the Phase 1 RMC-6236-001 clinical trial evaluating daraxonrasib in patients with previously treated metastatic PDAC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines announces first patient dosed in RASolve 301
- Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright
- Promising Developments in Revolution Medicines’ RAS(ON) Pipeline for NSCLC Treatment
- Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs
- Revolution Medicines price target lowered to $80 from $87 at Guggenheim